Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05995171
Other study ID # 2022_0483
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date November 14, 2023
Est. completion date November 14, 2026

Study information

Verified date February 2024
Source University Hospital, Lille
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Oesophageal atresia (OAEA), a malformation of the oesophagus present from birth, is characterized by the interruption of the continuity of the oesophagus, which then ends in a cul-de-sac. (Source: Fimatho) An operation is then required to restore continuity to the esophagus. Although this operation enables the vast majority of children to survive the neonatal period, health problems such as gastro-oesophageal reflux, eating difficulties, respiratory problems and growth problems persist throughout life. The aim of the project is to create a prospective cohort of adolescents aged 13/14, nested in the national AO registry. of adolescents born with esophageal atresia, including a biobank of esophageal mucosa and plasma blood samples. Once the clinical and omic data have been collected, the data will be transferred to the France Cohortes information system for analysis, in order to assess the long-term outcome of this rare disease and establish multi-omic profiles. Once the clinical data have been collected and the omics data (derived from analysis of the biobank's biological samples) have been generated, they will be analyzed by the project partners to assess the long-term outcome of OA and establish multiomic profiles. The raw data will be available on the France Cohorte platform.


Recruitment information / eligibility

Status Recruiting
Enrollment 300
Est. completion date November 14, 2026
Est. primary completion date November 14, 2026
Accepts healthy volunteers No
Gender All
Age group 13 Years to 14 Years
Eligibility Inclusion Criteria: - For the oesophagal atresia group : - Born with oesophageal atresia (AO) in France or in French overseas departments and territories - Operated at birth for an AO - Aged 13 or 14 during the recruitment period - Patient willing to comply with all study procedures and duration For the blood sub-study : - Upper GI endoscopy performed as part of care between 13 and 14 years of age with esophageal mucosal biopsy sampling - Patient having given written consent to participate in the study For the control arm: - Aged 13 or 14 during the recruitment period - Upper GI endoscopy performed as part of care for chronic or acute digestive signs to rule out organic etiology (peptic esophagitis, gastric esophagitis, eosinophilic esophagitis or ulcer) - Normal endoscopy and histology - No chronic progressive disease Exclusion Criteria: - For the oesophagal atresia arm : - Concurrent participation in an interventional trial and in the 3 months prior to inclusion - Parents refusing to participate in the study For the control arm : - Histologically non-normal esophageal biopsy - Parents refusing to participate in the study - Child with known organic pathology

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Questionnaire
Quality of life questionnaires will be used specifically for this research: Pediatric Quality of Life Invertory and EA-QoL

Locations

Country Name City State
France CHU de Lille Hôpital Jeanne de Flandre Lille Nord

Sponsors (2)

Lead Sponsor Collaborator
University Hospital, Lille Institut National de la Santé Et de la Recherche Médicale, France

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary prevalence of gastroesophageal reflux disease (GERD) in children born with esophageal atresia GERD = [pH/impedance-metry demonstrating pathological GERD and/or if lesions of peptic esophagitis are observed at an endoscopy in the year preceding the visit or if the child has a history of complicated GERD leading to anti-reflux surgery] 13-14 years
Secondary the prevalence of GERD at 13-14 years of age It will be determined from patient characteristics at birth, 1 year, 6 years and 13-14 years (ante-natal data, vital signs, presence of associated malformations, type of atresia, surgical procedures performed, surgical/digestive/respiratory/neuro-orthopaedic complications, type of diet and schooling). Birth,1 year, 6 years and 13-14 years
Secondary Quality of life, nutritional status and respiratory complications Quality of life= EA-QoL and PedsQL The quality of life of patients in adolescence will be assessed by means of the following quality of life scales at the age of 13-14 years: PedsQL (13) and EA-QoL (11) by both the patient and a parent. Scale scores will be calculated in accordance with the authors' instructions.
Nutritional status will be assessed by weight and height, and by calculating the weight/height z-score and BMI z-score using the World Health Organisation growth curves as a reference (14).
Frequency of respiratory complications, assessed during clinical examination (hacking cough during infections, chronic cough, asthma, exertional symptoms (cough, dyspnoea), atopy, wheezing and/or stridor/corniness).
13-14 years
Secondary Omics and multi omics profiles in esophageal biopsiesfor patient having 1 biopsie metabolites, proteins and methylation 13-14 years
Secondary Omics and multi omics profiles in esophageal biopsies for patient having more than 1 biopsie metabolites, proteins and methylation 13-14 years
Secondary Omics and multi omics profiles in plasma 13-14 years
See also
  Status Clinical Trial Phase
Recruiting NCT04072419 - Application of Enhanced Recovery After Surgery for Congenital Esophageal Atresia During Perioperative Period
Withdrawn NCT03127345 - Omega 3 Fatty Acid Treatment for Pediatric Musculoskeletal Health Phase 2
Completed NCT00226044 - Rectal and Oral Omeprazole Treatment of Reflux Disease in Infants. Phase 3
Completed NCT03615495 - Flourishâ„¢ Pediatric Esophageal Atresia
Completed NCT04901546 - Esophageal Atresia: a Natural Experiment of the Effects of Oral Inoculation on the Gut Microbiome N/A
Recruiting NCT03730454 - Transanastomotic Tube for Proximal Esophageal Atresia With Distal Tracheoesophageal Fistula Repair N/A
Recruiting NCT03455881 - Phenotypic and Genetic Assessment of Tracheal and Esophageal Birth Defects in Patients
Completed NCT05527873 - Respiratory Complications of Operated Esophageal Atresia in Children
Completed NCT04932746 - The Effect of Dexmedetomidine on Oxygen During One Lung Ventilation in Pediatric Surgery. N/A
Not yet recruiting NCT04259528 - Endoscopic Ultrasound Findings in Esophageal Atresia Following Surgical Repair N/A
Recruiting NCT06073158 - Molecular Signatures of Esophageal Atresia N/A
Not yet recruiting NCT03999008 - Oral Viscous Budesonide in Anastomotic Stricture After Esophageal Atresia Repair (OVB in EA) N/A
Completed NCT03415893 - High-resolution Esophageal Manometry N/A
Not yet recruiting NCT03023865 - Individualized Management for Long Gap Esophageal Atresia N/A
Recruiting NCT02883725 - National Register of Oesophageal Atresia
Not yet recruiting NCT04136795 - Evaluation of the Respiratory Impact After Conventional or Minimally Invasive Esophageal Atresia Surgery
Recruiting NCT03619408 - Management of Esophagitis Following Repair of Esophageal Atresia
Completed NCT05129930 - Fluid Overload and Pulmonary Function
Completed NCT02033772 - Prospective Data Collection of Patients < 6 Months of Age Undergoing Thoracoscopic Surgery N/A
Recruiting NCT03767673 - Cardiorespiratory Performance and Pulmonary Microbiome in Patients After Repair of Esophageal Atresia N/A